Achaogen (OTCMKTS:AKAOQ) versus Qualigen Therapeutics (NASDAQ:AIXC) Financial Comparison

Achaogen (OTCMKTS:AKAOQ) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Achaogen and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achaogen	N/A	N/A	N/A
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Achaogen and Qualigen Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achaogen	0	0	0	0	0.00
Qualigen Therapeutics	1	0	0	0	1.00

Valuation and Earnings

This table compares Achaogen and Qualigen Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achaogen	$8.73 million	0.14	-$186.51 million	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97 million	($6.47)	-0.16

Qualigen Therapeutics has lower revenue, but higher earnings than Achaogen.

Insider and Institutional Ownership

3.2% of Qualigen Therapeutics shares are held by institutional investors. 7.8% of Achaogen shares are held by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Achaogen has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

About Achaogen

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.